 SQZ Biotechnologies Company NYSE: SQZ has announced preclinical results from its Tolerizing Antigen Carrier TAC program, showing potential for application in various autoimmune diseases. Data will be presented at the 2021 Federation of Clinical Immunology Sciences annual meeting. 